Autopsy report · NCT01913301

A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure

“Sponsor lost funding”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 years 2 months after it had already started.
• Ran for about 1 year 5 months before it stopped.
• 134 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Cardiovascular Clinical Sciences Inc

Sponsor type

Industry

Conditions

Diastolic Heart Failure

Interventions

Alagebrium

Participants

134

Trials that died the same way

• Effects of Neuro-Stim System on Pain, Sleep, and Opioid Use
  “Lost funding from sponsor” (98% match in meaning)
• Mepolizumab for Eosinophilic Fasciitis
  “Funding lost from Sponsor.” (95% match in meaning)
• Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder
  “Sponsor withdrew funding” (86% match in meaning)
• Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone
  “Loss of Financial Sponsor” (86% match in meaning)
• Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
  “Funding withdrawn by sponsor” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.